Bap29varP, a variant of Bap29, influences the cell surface expression of the human P-glycoprotein

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 135-144

  Rao, Prema S ^a   Bickel, Ulrich ^a   Srivenugopal, Kalkunte S ^a   Rao, U Subrahmanyeswara ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bap29; Bap31; Cancer drug resistance; Multidrug resistance; P glycoprotein; Protein trafficking; Yeast two hybrid

Indexed keywords

CHAPERONE; GLYCOPROTEIN P; ISOPROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CELL STRAIN HT29; CELL STRAIN MCF 7; CELL SURFACE; CELL VACUOLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; PROTEIN VARIANT; TWO HYBRID SYSTEM; YEAST;

EID: 38749091263     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.135     Document Type: Article

References (38)

1. Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg BR, Reinhold W, Weinstein JN, Pommier Y, Paules RS and Gottesman MM: Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 66: 1397-1405, 2004.
2. Ueda K, Cardarelli C, Gottesman MM and Pastan I: Expression of a full-length cDNA for the human 'MDRI' gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008, 1987.
3. Choi KH, Chen CJ, Kriegler M and Roninson IB: An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 53: 519-529, 1988.
4. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986.
5. Hrycyna CA, Airan LE, Germann UA, Ambudkar SV, Pastan I and Gottesman MM: Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry 37: 13660-13673, 1998.
6. Germann UA, Willingham MC, Pastan I and Gottesman MM: Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry 29: 2295-2303, 1990.
7. Sauna ZE and Ambudkar SV: About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6: 13-23, 2007.
8. Sharom FJ: Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 84: 979-992, 2006.
9. Schamel WW, Kuppig S, Becker B, Gimborn K, Hauri HP and Reth M: A high-molecular-weight complex of membrane proteins BAP29/BAP31 is involved in the retention of membrane-bound IgD in the endoplasmic reticulum. Proc Natl Acad Sci USA 100: 9861-9866, 2003.
10. Breckenridge DG, Nguyen M, Kuppig S, Reth M and Shore GC: The procaspase-8 isoform, procaspase-8L, recruited to the BAP31 complex at the endoplasmic reticulum. Proc Natl Acad Sci USA 99: 4331-4336, 2002.
11. Paquet ME, Cohen-Doyle M, Shore GC and Williams DB: Bap29/31 influences the intracellular traffic of MHC class I molecules. J Immunol 172: 7548-7555, 2004.
12. Adachi T, Schamel WW, Kim KM, Watanabe T, Becker B, Nielsen PJ and Reth M: The specificity of association of the IgD molecule with the accessory proteins BAP31/BAP29 lies in the IgD transmembrane sequence. EMBO J 15: 1534-1541, 1996.
13. Annaert WG, Becker B, Kistner U, Reth M and Jahn R: Export of cellubrevin from the endoplasmic reticulum is controlled by BAP31. J Cell Biol 139: 1397-1410, 1997.
14. Ng FW, Nguyen M, Kwan T, Branton PE, Nicholson DW, Cromlish JA and Shore GC: p28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum. J Cell Biol 139: 327-338, 1997.
15. Ng FW and Shore GC: Bcl-XL cooperatively associates with the Bap31 complex in the endoplasmic reticulum, dependent on procaspase-8 and Ced-4 adaptor. J Biol Chem 273: 3140-3143, 1998.
16. Kim KM, Adachi T, Nielsen PJ, Terashima M, Lamers MC, Kohler G and Reth M: Two new proteins preferentially associated with membrane immunoglobulin D. EMBO J 13: 3793-3800, 1994.
17. Spiliotis ET, Manley H, Osorio M, Zuniga MC and Edidin M: Selective export of MHC class I molecules from the ER after their dissociation from TAP. Immunity 13: 841-851, 2000.
18. Stojanovic M, Germain M, Nguyen M and Shore GC: BAP31 and its caspase cleavage product regulate cell surface expression of tetraspanins and integrin-mediated cell survival. J Biol Chem 280: 30018-30024, 2005.
19. Lambert G, Becker B, Schreiber R, Boucherot A, Reth M and Kunzelmann K: Control of cystic fibrosis transmembrane conductance regulator expression by BAP31. J Biol Chem 276: 20340-20345, 2001.
20. Szczesna-Skorupa E and Kemper B: BAP31 is involved in the retention of cytochrome P450 2C2 in the endoplasmic reticulum. J Biol Chem 281: 4142-4148, 2006.
21. Rao US and Nuti SL: Identification of two different states of P-glycoprotein in its catalytic cycle: role of the linker region in the transition between these two states. J Biol Chem 278: 46576-46582, 2003.
22. Nuti SL, Mehdi A and Rao US: Activation of the human P-glycoprotein ATPase by trypsin. Biochemistry 39: 3424-3432, 2000.
23. Nuti SL and Rao US: Proteolytic cleavage of the linker region of the human P-glycoprotein modulates its ATPase function. J Biol Chem 277: 29417-29423, 2002.
24. Rao PS, Mallya KB, Srivenugopal KS, Balaji KC and Rao US: RNF2 interacts with the linker region of the human P-glycoprotein. Int J Oncol 29: 1413-1419, 2006.
25. Fairchild CR, Moscow JA, O'Brien EE and Cowan KH: Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferasepi. Mol Pharmacol 37: 801-809, 1990.
26. Rao PS, Govindarajan R, Mallya KB, West W and Rao US: Characterization of a new antibody raised against the NH2 terminus of P-glycoprotein. Clin Cancer Res 11: 5833-5839, 2005.
27. Mechetner EB and Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 89: 5824-5828, 1992.
28. Loo TW and Clarke DM: Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 272: 709-712, 1997.
29. Schinkel AH, Kemp S, Dolle M, Rudenko G and Wagenaar E: N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 268: 7474-7481, 1993.
30. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S and Ambudkar SV: Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol 173: 203-214, 2000.
31. Labialle S, Gayet L, Marthinet E, Rigal D and Baggetto LG: Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64: 943-948, 2002.
32. Skach WR, Calayag MC and Lingappa VR: Evidence for an alternate model of human P-glycoprotein structure and biogenesis. J Biol Chem 268: 6903-6908, 1993.
33. Skach WR and Lingappa VR: Amino-terminal assembly of human P-glycoprotein at the endoplasmic reticulum is directed by cooperative actions of two internal sequences. J Biol Chem 268: 23552-23561, 1993.
34. Skach WR and Lingappa VR: Transmembrane orientation and topogenesis of the third and fourth membrane-spanning regions of human P-glycoprotein (MDR1). Cancer Res 54: 3202-3209, 1994.
35. Al-Shawi MK, Polar MK, Omote H and Figler RA: Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem 278: 52629-52640, 2003.
36. Sauna ZE, Smith MM, Muller M and Ambudkar SV: Functionally similar vanadate-induced 8-azidoadenosine 5′-[alpha-(32)P]Diphosphate-trapped transition state intermediates of human P-glycoprotin are generated in the absence and presence of ATP hydrolysis. J Biol Chem 276: 21199-21208, 2001.
37. Chen EY, Bartlett MC, Loo TW and Clarke DM: The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 279: 39620-39627, 2004.
38. Kartner N, Augustinas O, Jensen TJ, Naismith AL and Riordan IR: Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1: 321-327, 1992.